Abstract：Objective To explore the antipsychotic drug use status in second-class hospital and its influence factor.Methods A total of 315 patients with schizophrenia were diagnosed with ICD-10 criteria who admitted to the mental healthy center in Jiangbei district of Chongqing were selected as subjects.A cross-sectional survey assessed by the self-compiled questionnaire.Results Of the 315 hospitalized patients,163(51.7%)used single drug and 152(48.3%)used drug combination.The second-generation antipsychotic drugs were dominant in mono-therapy(158 cases,50.2%),double second-generation antipsychotic drugs were dominant in poly-therapy(123 cases,39.0%).In the second generation antipsychotics,the frequency of drug use in the top three were Risperidone(47.30%),Clozapine(31.11%)and Aripiprazole(30.16%).The gender of patients in different medications groups was statistically significant(P＜0.05).The total duration of patients in the combined drug group was significantly longer than that of the single drug group,and the difference was statistically significant(P＜0.01).Logistic regression analysis showed that the course was the risk factor of drug combination(β=0.047,OR=0.047,95%CI=1.021-1.077,P＜0.01),longer disease duration was more inclined to choose drug combination,the age was the protection factor for drug selection(β=0.029,OR=0.029,95%CI=0949-0.994,P＜0.05),older patients was more inclined to choose single drug therapy.Conclusion At present,second-class hospitals are mainly treated with second-generation antipsychotics drugs,and single and combination drugs together play a role in the treatment of schizophrenia.
朱剑； 史战明； 温红霞； 孙蒙； 沈彦； 刘家胜； 陈登国； 黄彩虹. 二级医院抗精神病药物使用现况调查及影响因素分析[J]. 中国当代医药, 2018, 25(13): 173-176.
ZHU Jian； SHI Zhan-ming ；WEN Hong-xia ；SUN Meng； SHEN Yan ；LIU Jia-sheng； CHEN Deng-guo；HUANG Cai-hong. Survey of antipsychotic drug use status in second-class hospital and analysis of its influence factor. 中国当代医药, 2018, 25(13): 173-176.
Ruiz A，Branas A，Vicens M，et al.Antipsychotic monotherapy versus combination in schizophrenia：are there differences in cognition?[J].Eur Psychiatry，2016，33（3）：334.
[7]
Tuanthon B，Suphat S，Piyameth D，et al.Hospitalization and cost after switching from atypical to typical antipsychotics in schizophrenia patients in Thailand[J].Clinicoecon Outcomes Res，2016，8（1）：127-136.
Yoon HW，Lee JS，Park SJ，et al.Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia：a multicenter，open-label，prospective study[J].Clin Neuropharmacol，2016，39（6）：288-294.
[10]
Frank GK，Shott ME，Hagman JO，et al.The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa[J].Int J Eat Disord，2017，50（3）：447-450.
[11]
Suzuki H，Sekiguchi G.Influence of aripiprazole once monthly on clinical symptoms and cognitive function in two schizophrenia patients：preliminary results[J].Psychiatry Clin Neurosci，2016，70（1）：71-72.
[12]
Aouizerate B，Berna F，Blanc O，et al.Akathisia：prevalence and risk factors in a community-dwelling sample of patients with schizophrenia.Results from the FACE-SZ dataset[J].Schizophr Res，2015，169（1-3）：255-261.
京公网安备 11010502046607号